Phonetic: Abílita Bío

Keep updated, see our News page!

THE WORD ABILITA DERIVES FROM LATIN AND MEANS “TO MAKE POSSIBLE”.
OUR COMPANY IS IN FACT FOCUSED ON DEVELOPING TECHNOLOGIES
TO ENABLE DRUG DISCOVERY EFFORTS TARGETING THE MOST CHALLENGING MEMBRANE PROTEINS LIKE
G PROTEIN-COUPLED RECEPTORS (GPCRs), ION CHANNELS, AND TRANSPORTERS.

WE ARE LEVERAGING OUR PROPRIETARY ENABLED MEMBRANE PROTEIN (EMP™) TECHNOLOGY PLATFORM
TO DRIVE THE DISCOVERY OF BIOLOGICS AND SMALL MOLECULES FOR OUR PARTNERS
AND TO FUEL OUR INTERNAL PIPELINE

TRANSFORMING THE FIELD OF MEMBRANE PROTEIN DRUG DISCOVERY

WHAT IS OUR MISSION:

ENABLING DRUG DISCOVERY FOR INTRACTABLE MEMBRANE PROTEIN TARGETS, INCLUDING
G PROTEIN-COUPLED RECEPTORS, ION CHANNELS AND TRANSPORTER

Antibody Discovery

Compound Screening

Crystallography

THE MARKET FOR DRUGS TARGETING MULTI-SPAN MEMBRANE PROTEINS:

0%
Of marketed drugs target membrane proteins

$0B
Annual global revenue for GPCRs alone

>0
Medically relevant MP targets identified in the human genome

0
Therapeutic antibody approved worldwide

<0%
Of medically relevant membrane proteins with approved drugs

ONLY 15% HAVE BEEN DRUGGED: A TREMENDOUS UNMET MARKET OPPORTUNITY

THE CHALLENGE

Drug discovery targeting multi-span membrane proteins is inherently difficult due to the notoriously low stability and high conformational flexibility of these target classes, especially when removed from the cellular environment. This intrinsic characteristic of membrane proteins has greatly limited the success of protein-based small molecule screening and structure-guided drug discovery, as well as antibody discovery efforts.

OUR SOLUTION

Abilita Bio offers a technical solution through the generation of Enabled Membrane Proteins (EMPs™) for use in drug discovery and development, including antibody discovery programs. Providing enhanced full-protein antigens for antibody discovery represents a unique market opportunity, minimally available today to the Pharmaceutical Industry.